These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8931961)

  • 1. Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer.
    Wolff JM; Ittel T; Boeckmann W; Reinike T; Habib FK; Jakse G
    Eur Urol; 1996; 30(3):302-6. PubMed ID: 8931961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of skeletal alkaline phosphatase and prostate-specific antigen in the diagnosis of bone metastasis in cancer of the prostate.
    Wolff JM; Ittel T; Borchers H; Brauers A; Jakse G
    Urol Int; 1998 Oct; 61(1):12-6. PubMed ID: 9792976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphatase.
    Wolff JM; Ittel TH; Boeckmann W; Habib FK; Jakse G
    Anticancer Res; 1997; 17(4B):2995-7. PubMed ID: 9329584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?].
    Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU
    Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase.
    Wolff JM; Ittel TH; Borchers H; Boekels O; Jakse G
    Anticancer Res; 1999; 19(4A):2653-5. PubMed ID: 10470213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
    Lorente JA; Valenzuela H; Morote J; Gelabert A
    Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
    Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
    J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
    Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
    Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal alkaline phosphatase: a marker for individual follow-up in patients with advanced prostatic cancer.
    Wechsel HW; Petri E; Bichler KH
    Urol Int; 1997; 58(2):80-3. PubMed ID: 9096267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
    Wolff JM; Bares R; Jung PK; Buell U; Jakse G
    Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker.
    Gillatt D; Reynard JM
    Br J Urol; 1995 Mar; 75(3):341-6. PubMed ID: 7537603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
    Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G
    Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
    Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
    Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
    Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
    Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
    Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
    Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
    Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK
    Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
    Akimoto S; Akakura K; Shimazaki J
    Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.